EMA accepts marketing application for Trastuzumab and Pegfilgrastim
Mylan and Biocon announced that the European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Applications (MAA) for proposed biosimilar trastuzumab and…
Read More...
Read More...